This study compared two spirometry thresholds—Global Initiative for Obstructive Lung Disease (GOLD) and Global Lung Initiative (GLI)—to evaluate their impact on classifying older patients who smoke ...

Methods: COPD risk is evaluated for adults to make an early COPD risk decision from the perspective ... The COPD stage is diagnosed from stages 0 to IV according to (Global Initiative for Chronic ...

The GOLD system previously classified COPD ... and your blood oxygen levels are also low. You’re at risk of developing COPD complications like heart or lung failure. A grade 4 score on your ...

Area under the curve went up with use of a lung function questionnaire score plus a COPD genetic risk score. The ability to predict spirometry-defined COPD was significantly better when a modified ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...

Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity ...

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive ...

Conclusions The prevalence of airflow limitation ranged from 8% to 17% using GOLD and four different LLN criteria; however, identified individuals with the five different criteria had similar risk of ...

ADULTS who began smoking before the age of 15 have a significantly higher risk of chronic obstructive pulmonary disease (COPD) than those who started later, even when adjusting for smoking history and ...

It isn’t pleasant, but there are ways to manage it. Doctors use stages to describe how severe your COPD is. This system is called the GOLD staging or grading system. COPD sneaks up on you ...

Both SGLT2 inhibitors and GLP-1s lowered moderate or severe COPD exacerbation risk vs. DPP-4 inhibitors. Weight loss and SGLT2 inhibitors’ glucosuria effect may explain the findings. Sodium ...

SODIUM-GLUCOSE cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with a reduced risk of moderate or severe chronic obstructive pulmonary ...